Lung Cancer

Expert faculty review and share their insights and perspectives on key findings in lung cancer presented at the 2020 ASCO Annual Meeting.

Share

Program Content

Activities

  • ASCO 2020: Key Lung Cancer Studies
    Key Studies in Lung Cancer: Independent Conference Coverage of the ASCO 2020 Scientific Meeting
    Conference Coverage
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 25, 2020

    Expires: September 24, 2021

  • EP: Lung Cancer
    ExpressPoints: Key Studies in Lung Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 25, 2020

    Expires: September 24, 2021

Activities

Lurbinectedin Plus Irinotecan
Phase Ib/II Trial of Lurbinectedin Plus Irinotecan in Patients With Advanced Solid Tumors
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 04, 2020

Expires: June 03, 2021

KEYNOTE-604
KEYNOTE-604 Final Analysis: Addition of Pembrolizumab to Etoposide and Platinum in Extensive-Stage SCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 01, 2020

Expires: May 31, 2021

CASPIAN
CASPIAN: Phase III Study of First-line Durvalumab + Tremelimumab + EP vs Durvalumab + EP vs EP Alone in Extensive-Stage SCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 01, 2020

Expires: May 31, 2021

ADJUVANT-CTONG 1104
ADJUVANT-CTONG 1104: Final OS Analysis of Phase III Study of Adjuvant Gefitinib vs Chemotherapy in Chinese Patients With Resected EGFR-Mutated NSCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2020

Expires: June 08, 2021

CheckMate 227: 3-Year Update
First-line Nivolumab Plus Ipilimumab vs Chemotherapy in Advanced NSCLC: 3-Year Update of CheckMate 227 Part 1
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 01, 2020

Expires: May 31, 2021

CheckMate 9LA
CheckMate 9LA: Nivolumab and Ipilimumab Plus 2 Cycles of Platinum-Doublet Chemotherapy vs 4 Cycles Chemotherapy as First-line Treatment for Advanced Non-small Cell Lung Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 02, 2020

Expires: June 01, 2021

CITYSCAPE: Tiragolumab
Phase II CITYSCAPE: Addition of Tiragolumab, an Anti-TIGIT Antibody, to First-line Atezolizumab in PD-L1–Selected Metastatic NSCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2020

Expires: June 04, 2021

DESTINY-Lung01
Phase II DESTINY-Lung01: Interim Analysis of Trastuzumab Deruxtecan in Patients With HER2-Mutated NSCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: May 30, 2020

Expires: May 29, 2021

SINDAS Interim Analysis
Phase III SINDAS: Interim Analysis of First-line EGFR TKI With vs Without SBRT in Patients With EGFR-Mutated Oligometastatic NSCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2020

Expires: June 04, 2021

GEOMETRY: Capmatinib in METamp+ NSCLC
Phase II GEOMETRY mono-1: Capmatinib in Patients With NSCLC and High MET Amplification
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 04, 2020

Expires: June 03, 2021

ARROW: Pralsetinib in <i>RET</i>+ NSCLC
Phase I/II ARROW: Registrational Dataset of RET Inhibitor Pralsetinib (BLU-667) in Patients With Advanced RET Fusion–Positive NSCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2020

Expires: June 07, 2021

RESILIENT: Liposomal Irinotecan
RESILIENT Part 1: Phase II Study of Liposomal Irinotecan After Platinum Chemotherapy in Small-Cell Lung Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 03, 2020

Expires: June 02, 2021

ADAURA: Adj Osimertinib
Phase III ADAURA: Adjuvant Osimertinib vs Placebo After Complete Resection in Patients With Stage IB-IIIA EGFR-Mutated NSCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 01, 2020

Expires: May 31, 2021

Provided by

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Daiichi Sankyo, Inc.

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.